Celltrion, Inc.: Experts Share Their “Real World” Experience Of Treating People With Inflammatory Bowel Disease (IBD) With Biosimilar Anti-Tnfa Monoclonal Antibody (Mab)
VIENNA--(BUSINESS WIRE)--Clinical experience presented today at the Celltrion Healthcare satellite symposium during UEGW 2014 builds the evidence base for treating patients with IBD (Crohn’s disease and ulcerative colitis) with a biosimilar monoclonal antibody (mAb) infliximab.
Infliximab is an anti-TNF therapy for treating patients with IBD1,2,, and is considered a therapy for controlling disease symptoms over the long term.3,4
Leading expert, Jørgen Jahnsen, Professor of Gastroenterology, University of Oslo, Norway, reported on his “real-world” clinical experience of treating people with both Crohn’s disease and ulcerative colitis with the first biosimilar mAb anti-TNFa approved by the European Medicines Agency (EMA) and licensed for use in Norway. A statistically significant reduction in disease activity at week fourteen was reported in 46 IBD patients (26 Crohn’s and 20 ulcerative colitis) following treatment with three infusions.
Help employers find you! Check out all the jobs and post your resume.
Infliximab is an anti-TNF therapy for treating patients with IBD1,2,, and is considered a therapy for controlling disease symptoms over the long term.3,4
Leading expert, Jørgen Jahnsen, Professor of Gastroenterology, University of Oslo, Norway, reported on his “real-world” clinical experience of treating people with both Crohn’s disease and ulcerative colitis with the first biosimilar mAb anti-TNFa approved by the European Medicines Agency (EMA) and licensed for use in Norway. A statistically significant reduction in disease activity at week fourteen was reported in 46 IBD patients (26 Crohn’s and 20 ulcerative colitis) following treatment with three infusions.
Help employers find you! Check out all the jobs and post your resume.